Original: May 11, 2021 | Updated: December 22,2025
Read time: 2 mins
Advancing precision respiratory diagnostics just got a major boost at Diag-Nose.
What would you do with $689,000 in this 2021 Winter?
At Diag-Nose, we are putting our answer into action.
Backed by Artesian Venture Capital and Specialty Physician Associates (SPA), we have successfully secured $689,000 in a 2021 pre-seed round, putting it to good use in investigating nasal fluid as a window for precision diagnostics for patients with chronic respiratory diseases.
This isn’t just a funding milestone - it’s a vote of confidence in our mission.
Turning nasal fluid into a window for precision diagnostics in respiratory and ENT care (and with COVID-19 still looming over us, this may be more important than ever).
What is the importance of this funding for our mission?
The funding provides crucial support for our research team, empowering us to push the boundaries of what’s possible in respiratory diagnostics. It enables us to:
- Accelerate research and development, bringing breakthroughs from concept to reality faster.
- Expand clinical trials, generating the critical data necessary to navigate regulatory pathways.
- Forge meaningful partnerships that translate scientific innovation into real-world patient impact.
- Refine and advance our technology through cutting-edge R&D, ensuring precision and reliability.
This support brings us ever closer to delivering nasal biomarker diagnostics with the potential to transform precision medicine in respiratory care.
Dr. Brian Wang, Co-Chief Scientific Officer of Diag-Nose, highlights the significance of this milestone:
“As founders, we are grateful for such significant support from our mentors and networks. Launching a new venture remotely across continents has been challenging, but our team’s commitment to improving patient care has pushed us to be just as innovative in collaboration as we are in diagnostics.”
With this momentum, we are not just advancing science - we are shaping a future where respiratory care is smarter, faster, and more personalized.
Looking Beyond the Lab: How Diag-Nose is Transforming Respiratory Care
It’s no exaggeration to say that accurately diagnosing and monitoring respiratory diseases remains one of healthcare’s biggest unmet challenges.
At Diag-Nose, we’re tackling this challenge head-on with a non-invasive diagnostic platform that transforms nasal fluid into actionable insights.
Our technology empowers clinicians to tailor treatments, reduce unnecessary antibiotics, and - most importantly - improve outcomes for patients when it matters most.
Keep an eye out for our latest breakthrough and behind-the scenes updates by following us on LinkedIn!